DMSE Spring Seminar Series Presents Paul McCormac

Description

Paul McCormac, chief technology officer of Lexeo Therapeutics, will give a talk titled "Delivering the Promise of Gene Therapy Beyond Rare Disease" for the Department of Materials Science & Engineering's Spring Seminar Series.

All in-person events at Johns Hopkins must follow university COVID-19 policies. See current guidelines online. This is a hybrid event; please email DMSE@jhu.edu for the Zoom link.

Abstract:

Recent approvals including Luxturna® and Zolgensma® have demonstrated the transformational impact AAV gene therapy can have for rare monogenic diseases. The approval and distribution of mRNA vaccines has demonstrated the potential for nucleic acid medicines to be impactful globally. This talk will focus on the historical context of AAV gene therapy development and manufacturing and to deliver these transformational medicines to very large patient populations by the application of bioprocess engineering and advanced analytics.